Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
asparaginase (elspar) (1 trial)
cyclophosphamide (cytoxan) (1 trial)
cytarabine (cytosar-u) (2 trials)
daunorubicin (cerubidine) (1 trial)
doxorubicin (Doxil) (1 trial)
leucovorin (2 trials)
mercaptopurine (purinethol) (1 trial)
naltrexone (revia) (2 trials)
prednisone (meticorten) (2 trials)
tioguanine (Lanvis) (1 trial)
urea (2 trials)
vincristine (oncovin) (2 trials)
allogeneic hematopoietic stem cells (Hemacord) (1 trial)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)
autologous hematopoietic stem cells (1 trial)
busulfan (Myleran) (1 trial)
carboplatin (paraplatin) (1 trial)
carmustine (bicnu) (1 trial)
cyclosporine (sandimmune) (1 trial)
etoposide (vepesid) (1 trial)
idarubicin (idamycin) (1 trial)
ifosfamide (ifex) (1 trial)
lomustine (1 trial)
melphalan (alkeran) (1 trial)
mitoxantrone (novantrone) (1 trial)
thiotepa (1 trial)
vinblastine (velban) (1 trial)
Lymphoma (Phase 3)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)
Trials (2 total)
Trial APIs (27 total)